Advanced search
Publication Cover
Expert Opinion on Therapeutic Targets Volume 12, 2008 - Issue 9
Submit an article Journal homepage
198
Views
79
CrossRef citations to date
0
Altmetric
Review

NF-κB in carcinoma therapy and prevention

Matthew Brown National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD, USA
,
Jonah Cohen National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD, USA
,
Pattatheyil Arun National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD, USA
,
Zhong Chen National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD, USA
&
Carter Van Waes National Institute on Deafness and Other Communication Disorders, Head and Neck Surgery Branch, Bethesda, MD, USA; National Cancer Institute, Center for Cancer Research, Radiation Oncology Branch, Bethesda, MD, USA; Chief, Head and Neck Surgery Branch, Clinical Director National Institute on Deafness and Other Communication Disorders, NIH, Head and Neck Surgery Branch, Building 10 CRC Room 4-2732, Bethesda, MD 20892, USA +1 301 402 2001; +1 301 402 1140; [email protected]
Pages 1109-1122 | Published online: 12 Aug 2008

Bibliography

  • Hayden MS, Ghosh S. Shared principles in NF-κB signaling. Cell 2008;132(3):344-62
  • Hoffmann A, Baltimore D. Circuitry of nuclear factor κB signaling. Immunol Rev 2006;210:171-86
  • Barroga CF, Stevenson JK, Schwarz EM, Verma IM. Constitutive phosphorylation of IκBα by casein kinase II. Proc Natl Acad Sci USA 1995;92(17):7637-41
  • Yu M, Yeh J, Van Waes C. Protein kinase casein kinase 2 mediates inhibitor-κB kinase and aberrant nuclear factor-κB activation by serum factor(s) in head and neck squamous carcinoma cells. Cancer Res 2006;66(13):6722-31
  • Bancroft CC, Chen Z, Yeh J, et al. Effects of pharmacologic antagonists of epidermal growth factor receptor, PI3K and MEK signal kinases on NF-κB and AP-1 activation and IL-8 and VEGF expression in human head and neck squamous cell carcinoma lines. Int J Cancer 2002;99(4):538-48
  • Biswas DK, Cruz AP, Ganzberger E, Pardee AB. Epidermal Growth Factor-induced nuclear factor kappa B activation: a major pathway cell-cycle progression in estrogen-receptor negative breast cancer cells. Proc Natl Acad Sci USA 2000;97:8542-7
  • Wolf JS, Chen Z, Dong G, et al. IL (interleukin)-1α promotes nuclear factor-κB and AP-1-induced IL-8 expression, cell survival, and proliferation in head and neck squamous cell carcinomas. Clin Cancer Res 2001;7(6):1812-20
  • Sakurai H, Chiba H, Miyoshi H, et al. IκB kinases phosphorylate NF-κB p65 subunit on serine 536 in the transactivation domain. J Biol Chem 1999;274(43):30353-6
  • Wang D, Westerheide SD, Hanson JL, Baldwin AS Jr. Tumor necrosis factor α-induced phosphorylation of RelA/p65 on Ser529 is controlled by casein kinase II. J Biol Chem 2000;275(42):32592-7
  • Zhong H, Voll RE, Ghosh S. Phosphorylation of NF-κB p65 by PKA stimulates transcriptional activity by promoting a novel bivalent interaction with the coactivator CBP/p300. Mol Cell 1998;1(5):661-71
  • Vermeulen L, De Wilde G, Van Damme P, et al. Transcriptional activation of the NF-κB p65 subunit by mitogen- and stress-activated protein kinase-1 (MSK1). EMBO J 2003;22(6):1313-24
  • Madrid LV, Mayo MW, Reuther JY, Baldwin AS Jr. Akt stimulates the transactivation potential of the RelA/p65 Subunit of NF-κB through utilization of the IκB kinase and activation of the mitogen-activated protein kinase p38. J Biol Chem 2001;276(22):18934-40
  • Madrid LV, Wang CY, Guttridge DC, et al. Akt suppresses apoptosis by stimulating the transactivation potential of the RelA/p65 subunit of NF-κB. Mol Cell Biol 2000;20(5):1626-38
  • Tergaonkar V, Perkins ND. p53 and NF-κB crosstalk: IKKα tips the balance. Mol Cell 2007;26(2):158-9
  • Aggarwal BB, Shishodia S, Sandur SK, et al. Inflammation and cancer: how hot is the link? Biochem Pharmacol 2006;72(11):1605-21
  • Baldwin AS. Control of oncogenesis and cancer therapy resistance by the transcription factor NF-κB. J Clin Invest 2001;107(3):241-6
  • Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-κB pathway. J Clin Invest 2001;107(2):143-51
  • Van Waes C. Nuclear factor-κB in development, prevention, and therapy of cancer. Clin Cancer Res 2007;13(4):1076-82
  • Tsurutani J, Castillo SS, Brognard J, et al. Tobacco components stimulate Akt-dependent proliferation and NFκB-dependent survival in lung cancer cells. Carcinogenesis 2005;26(7):1182-95
  • Huang TT, Wuerzberger-Davis SM, Wu ZH, Miyamoto S. Sequential modification of NEMO/IKKγ by SUMO-1 and ubiquitin mediates NF-κB activation by genotoxic stress. Cell 2003;115(5):565-76
  • Dajee M, Lazarov M, Zhang JY, et al. NF-κB blockade and oncogenic Ras trigger invasive human epidermal neoplasia. Nature 2003;421(6923):639-43
  • Sakurai T, Maeda S, Chang L, Karin M. Loss of hepatic NF-κB activity enhances chemical hepatocarcinogenesis through sustained c-Jun N-terminal kinase 1 activation. Proc Natl Acad Sci USA 2006;103(28):10544-51
  • Luedde T, Beraza N, Kotsikoris V, et al. The role of NF-κB in hepatocarcinogenesis: promoter or suppressor? J Hepatol 2007;47(2):307-9
  • Pikarsky E, Porat RM, Stein I, et al. NF-κB functions as a tumour promoter in inflammation-associated cancer. Nature 2004;431(7007):461-6
  • Loukinova E, Chen Z, Van Waes C, Dong G. Expression of proangiogenic chemokine Gro 1 in low and high metastatic variants of Pam murine squamous cell carcinoma is differentially regulated by IL-1α, EGF and TGF-β1 through NF-κB dependent and independent mechanisms. Int J Cancer 2001;94(5):637-44
  • Asano T, Yao Y, Zhu J, et al. The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cells. Oncogene 2004;23(53):8571-80
  • Emmerich F, Meiser M, Hummel M, et al. Overexpression of I kappa B alpha without inhibition of NF-κB activity and mutations in the I kappa B alpha gene in Reed-Sternberg cells. Blood 1999;94(9):3129-34
  • Wood KM, Roff M, Hay RT. Defective IκBα in Hodgkin cell lines with constitutively active NF-κB. Oncogene 1998;16(16):2131-9
  • Annunziata CM, Davis RE, Demchenko Y, et al. Frequent engagement of the classical and alternative NF-κB pathways by diverse genetic abnormalities in multiple myeloma. Cancer Cell 2007;12(2):115-30
  • Allen C, Saigal K, Nottingham L, et al. Bortezomib-induced apoptosis with limited clinical response is accompanied by inhibition of canonical but not alternative NF-κB pathway subunits in head and neck cancer. Clin Cancer Res 2008;14: In press
  • Dan HC, Adli M, Baldwin AS. Regulation of mammalian target of rapamycin activity in PTEN-inactive prostate cancer cells by IκB kinase α. Cancer Res 2007;67(13):6263-9
  • Chung CH, Parker JS, Ely K, et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-κB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res 2006;66(16):8210-8
  • Dong G, Loukinova E, Chen Z, et al. Molecular profiling of transformed and metastatic murine squamous carcinoma cells by differential display and cDNA microarray reveals altered expression of multiple genes related to growth, apoptosis, angiogenesis, and the NF-κB signal pathway. Cancer Res 2001;61(12):4797-808
  • Loercher A, Lee TL, Ricker JL, et al. Nuclear factor-κB is an important modulator of the altered gene expression profile and malignant phenotype in squamous cell carcinoma. Cancer Res 2004;64(18):6511-23
  • Lee TL, Yang XP, Yan B, et al. A novel nuclear factor-κB gene signature is differentially expressed in head and neck squamous cell carcinomas in association with TP53 status. Clin Cancer Res 2007;13(19):5680-91
  • Yan B, Chen G, Saigal K, et al. Systems biology-defined NF-κB regulons, interacting signal pathways and networks are implicated in the malignant phenotype of head and neck cancer cell lines differing in p53 status. Genome Biol 2008;9(3):R53. Published online 11 March 2008, doi:10.1186/gb-2008-9-3-r53
  • Yan B, Yang X, Lee TL, et al. Genome-wide identification of novel expression signatures reveal distinct patterns and prevalence of binding motifs for p53, nuclear factor-κB and other signal transcription factors in head and neck squamous cell carcinoma. Genome Biol 2007;8(5):R78. Published online 11 May 2007, doi:10.1186/gb-2007-8-5-r78
  • Hinz M, Lemke P, Anagnostopoulos I, et al. Nuclear factor κB-dependent gene expression profiling of Hodgkin's disease tumor cells, pathogenetic significance, and link to constitutive signal transducer and activator of transcription 5a activity. J Exp Med 2002;196(5):605-17
  • Staudt LM. Gene expression profiling of lymphoid malignancies. Ann Rev Med 2002;53:303-18
  • Van Laere SJ, Van der Auwera I, Van den Eynden GG, et al. Nuclear factor-κB signature of inflammatory breast cancer by cDNA microarray validated by quantitative real-time reverse transcription-PCR, immunohistochemistry, and nuclear factor-κB DNA-binding. Clin Cancer Res 2006;12(11 Pt 1):3249-56
  • Chen C, Edelstein LC, Gelinas C. The Rel/NF-κB family directly activates expression of the apoptosis inhibitor Bcl-xL. Mol Cell Biol 2000;20(8):2687-95
  • Guttridge DC, Albanese C, Reuther JY, et al. NF-κB controls cell growth and differentiation through transcriptional regulation of cyclin D1. Mol Cell Biol 1999;19(8):5785-99
  • Wang CY, Mayo MW, Korneluk RG, et al. NF-κB antiapoptosis: induction of TRAF1 and TRAF2 and c-IAP1 and c-IAP2 to suppress caspase-8 activation. Science 1998;281(5383):1680-3
  • Richmond A. NF-κB, chemokine gene transcription and tumour growth. Nat Rev 2002;2(9):664-74
  • Adams J. Proteasome inhibition: a novel approach to cancer therapy. Trends Mol Med 2002;8(4 Suppl):S49-54
  • Sunwoo JB, Chen Z, Dong G, et al. Novel proteasome inhibitor PS-341 inhibits activation of nuclear factor-κB, cell survival, tumor growth, and angiogenesis in squamous cell carcinoma. Clin Cancer Res 2001;7(5):1419-28
  • Williams S, Pettaway C, Song R, et al. Differential effects of the proteasome inhibitor bortezomib on apoptosis and angiogenesis in human prostate tumor xenografts. Mol Cancer Ther 2003;2(9):835-43
  • Iqbal M, Chatterjee S, Kauer JC, et al. Potent inhibitors of proteasome. J Med Chem 1995;38(13):2276-7
  • Lun M, Zhang PL, Pellitteri PK, et al. Nuclear factor-kappaB pathway as a therapeutic target in head and neck squamous cell carcinoma: pharmaceutical and molecular validation in human cell lines using Velcade and siRNA/NF-κB. Ann Clin Lab Sci 2005;35(3):251-8
  • Nawrocki ST, Carew JS, Pino MS, et al. Aggresome disruption: a novel strategy to enhance bortezomib-induced apoptosis in pancreatic cancer cells. Cancer Res 2006;66(7):3773-81
  • Adachi M, Zhang Y, Zhao X, et al. Synergistic effect of histone deacetylase inhibitors FK228 and m-carboxycinnamic acid bis-hydroxamide with proteasome inhibitors PSI and PS-341 against gastrointestinal adenocarcinoma cells. Clin Cancer Res 2004;10(11):3853-62
  • Zhu H, Zhang L, Dong F, et al. Bik/NBK accumulation correlates with apoptosis-induction by bortezomib (PS-341, Velcade) and other proteasome inhibitors. Oncogene 2005;24(31):4993-9
  • Lun M, Zhang PL, Siegelmann-Danieli N, et al. Intracellular inhibitory effects of Velcade correlate with morphoproteomic expression of phosphorylated-nuclear factor-κB and p53 in breast cancer cell lines. Ann Clin Lab Sci 2005;35(1):15-24
  • Hideshima T, Chauhan D, Richardson P, et al. NF-κB as a therapeutic target in multiple myeloma. J Biol Chem 2002;277(19):16639-47
  • Kisselev AF, Goldberg AL. Proteasome inhibitors: from research tools to drug candidates. Chem Biol 2001;8(8):739-58
  • Chen Z, Ricker JL, Malhotra PS, et al. Bortezomib exhibits differential anti-tumor activity in head and neck tumor xenografts and cells which correspond to proteasome, NF-κB and AP-1 activities in vitro. Mol Cancer Ther 2008;7: In press
  • Van Waes C, Chang AA, Lebowitz PF, et al. Inhibition of nuclear factor-κB and target genes during combined therapy with proteasome inhibitor bortezomib and reirradiation in patients with recurrent head-and-neck squamous cell carcinoma. Int J Radiat Oncol Biol Phys 2005;63(5):1400-12
  • Hovstadius P, Larsson R, Jonsson E, et al. A phase I study of CHS 828 in patients with solid tumor malignancy. Clin Cancer Res 2002;8(9):2843-50
  • Ravaud A, Cerny T, Terret C, et al. Phase I study and pharmacokinetic of CHS-828, a guanidino-containing compound, administered orally as a single dose every 3 weeks in solid tumours: an ECSG/EORTC study. Eur J Cancer 2005;41(5):702-7
  • Burke JR, Pattoli MA, Gregor KR, et al. BMS-345541 is a highly selective inhibitor of IκB kinase that binds at an allosteric site of the enzyme and blocks NF-κB-dependent transcription in mice. J Biol Chem 2003;278(3):1450-6
  • Yang J, Amiri KI, Burke JR, et al. BMS-345541 targets inhibitor of κB kinase and induces apoptosis in melanoma: involvement of nuclear factor κB and mitochondria pathways. Clin Cancer Res 2006;12(3 Pt 1):950-60
  • Yang J, Pan WH, Clawson GA, Richmond A. Systemic targeting inhibitor of κB kinase inhibits melanoma tumor growth. Cancer Res 2007;67(7):3127-34
  • Hideshima T, Neri P, Tassone P, et al. MLN120B, a novel IκB kinase β inhibitor, blocks multiple myeloma cell growth in vitro and in vivo. Clin Cancer Res 2006;12(19):5887-94
  • Castro AC, Dang LC, Soucy F, et al. Novel IKK inhibitors: β-carbolines. Bioorg Med Chem Lett 2003;13(14):2419-22
  • Yemelyanov A, Gasparian A, Lindholm P, et al. Effects of IKK inhibitor PS1145 on NF-κB function, proliferation, apoptosis and invasion activity in prostate carcinoma cells. Oncogene 2006;25(3):387-98
  • Domingo-Domenech J, Oliva C, Rovira A, et al. Interleukin 6, a nuclear factor-κB target, predicts resistance to docetaxel in hormone-independent prostate cancer and nuclear factor-κB inhibition by PS-1145 enhances docetaxel antitumor activity. Clin Cancer Res 2006;12(18):5578-86
  • Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of inhibitor of nuclear factor-κB phosphorylation increases the efficacy of paclitaxel in in vitro and in vivo ovarian cancer models. Clin Cancer Res 2004;10(22):7645-54
  • Mabuchi S, Ohmichi M, Nishio Y, et al. Inhibition of NFκB increases the efficacy of cisplatin in in vitro and in vivo ovarian cancer models. J Biol Chem 2004;279(22):23477-85
  • Duncan JS, Litchfield DW. Too much of a good thing: the role of protein kinase CK2 in tumorigenesis and prospects for therapeutic inhibition of CK2. Biochim Biophys Acta 2008;1784(1):33-47
  • Yde CW, Frogne T, Lykkesfeldt AE, et al. Induction of cell death in antiestrogen resistant human breast cancer cells by the protein kinase CK2 inhibitor DMAT. Cancer Lett 2007;256(2):229-37
  • Mishra S, Pertz V, Zhang B, et al. Treatment of P190 Bcr/Abl lymphoblastic leukemia cells with inhibitors of the serine/threonine kinase CK2. Leukemia 2007;21(1):178-80
  • Patel D, Shukla S, Gupta S. Apigenin and cancer chemoprevention: progress, potential and promise (review). Int J Oncol 2007;30(1):233-45
  • Hessenauer A, Montenarh M, Gotz C. Inhibition of CK2 activity provokes different responses in hormone-sensitive and hormone-refractory prostate cancer cells. Int J Oncol 2003;22(6):1263-70
  • Landesman-Bollag E, Song DH, Romieu-Mourez R, et al. Protein kinase CK2: signaling and tumorigenesis in the mammary gland. Mol Cell Biochem 2001;227(1-2):153-65
  • Shukla S, Gupta S. Molecular targets for apigenin-induced cell cycle arrest and apoptosis in prostate cancer cell xenograft. Mol Cancer Ther 2006;5(4):843-52
  • Ahmad KA, Wang G, Slaton J, et al. Targeting CK2 for cancer therapy. Anti-cancer Drugs 2005;16(10):1037-43
  • Slaton JW, Unger GM, Sloper DT, et al. Induction of apoptosis by antisense CK2 in human prostate cancer xenograft model. Mol Cancer Res 2004;2(12):712-21
  • Chadwick CC, Chippari S, Matelan E, et al. Identification of pathway-selective estrogen receptor ligands that inhibit NF-κB transcriptional activity. Proc Natl Acad Sci USA 2005;102(7):2543-8
  • Biswas DK, Shi Q, Baily S, et al. NF-κB activation in human breast cancer specimens and its role in cell proliferation and apoptosis. Proc Natl Acad Sci USA 2004;101(27):10137-42
  • Takada Y, Bhardwaj A, Potdar P, Aggarwal BB. Nonsteroidal anti-inflammatory agents differ in their ability to suppress NF-κB activation, inhibition of expression of cyclooxygenase-2 and cyclin D1, and abrogation of tumor cell proliferation. Oncogene 2004;23(57):9247-58
  • Forman BM, Tontonoz P, Chen J, et al. 15-Deoxy-Δ 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ. Cell 1995;83(5):803-12
  • Yu K, Bayona W, Kallen CB, et al. Differential activation of peroxisome proliferator-activated receptors by eicosanoids. J Biol Chem 1995;270(41):23975-83
  • Su CG, Wen X, Bailey ST, et al. A novel therapy for colitis utilizing PPAR-γ ligands to inhibit the epithelial inflammatory response. J Clin Invest 1999;104(4):383-9
  • Keshamouni VG, Arenberg DA, Reddy RC, et al. PPAR-γ activation inhibits angiogenesis by blocking ELR+CXC chemokine production in non-small cell lung cancer. Neoplasia 2005;7(3):294-301
  • Yamamoto Y, Yin MJ, Lin KM, Gaynor RB. Sulindac inhibits activation of the NF-κB pathway. J Biol Chem 1999;274(38):27307-14
  • Yin MJ, Yamamoto Y, Gaynor RB. The anti-inflammatory agents aspirin and salicylate inhibit the activity of IκB kinase-β. Nature 1998;396(6706):77-80
  • Yan F, Polk DB. Aminosalicylic acid inhibits IκB kinase α phosphorylation of IκBα in mouse intestinal epithelial cells. J Biol Chem 1999;274(51):36631-6
  • Stark LA, Din FV, Zwacka RM, Dunlop MG. Aspirin-induced activation of the NF-κB signaling pathway: a novel mechanism for aspirin-mediated apoptosis in colon cancer cells. FASEB J 2001;15(7):1273-5
  • Chan AT, Giovannucci EL, Schernhammer ES, et al. A prospective study of aspirin use and the risk for colorectal adenoma. Ann Intern Med 2004;140(3):157-66
  • Sandler RS, Halabi S, Baron JA, et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N Engl J Med 2003;348(10):883-90
  • Berman KS, Verma UN, Harburg G, et al. Sulindac enhances tumor necrosis factor-α-mediated apoptosis of lung cancer cell lines by inhibition of nuclear factor-κB. Clin Cancer Res 2002;8(2):354-60
  • Palayoor ST, Youmell MY, Calderwood SK, et al. Constitutive activation of IκB kinase α and NF-κB in prostate cancer cells is inhibited by ibuprofen. Oncogene 1999;18(51):7389-94
  • Stark LA, Dunlop MG. Nucleolar sequestration of RelA (p65) regulates NF-κB-driven transcription and apoptosis. Mol Cell Biol 2005;25(14):5985-6004
  • Shishodia S, Koul D, Aggarwal BB. Cyclooxygenase (COX)-2 inhibitor celecoxib abrogates TNF-induced NF-κB activation through inhibition of activation of IκBα kinase and Akt in human non-small cell lung carcinoma: correlation with suppression of COX-2 synthesis. J Immunol 2004;173(3):2011-22
  • Liu JF, Zhang SW, Jamieson GG, et al. The effects of a COX-2 inhibitor meloxicam on squamous cell carcinoma of the esophagus in vivo. Int J Cancer 2008;122(7):1639-44
  • Liu JF, Jamieson GG, Drew PA, et al. Aspirin induces apoptosis in oesophageal cancer cells by inhibiting the pathway of NF-κB downstream regulation of cyclooxygenase-2. ANZ J Surg 2005;75(11):1011-6
  • Dasgupta K, Di Cesar D, Ghosn J, et al. Association between nonsteroidal anti-inflammatory drugs and prostate cancer occurrence. Cancer J 2006;12(2):130-5
  • Wahl C, Liptay S, Adler G, Schmid RM. Sulfasalazine: a potent and specific inhibitor of nuclear factor kappa B. J Clin Invest 1998;101(5):1163-74
  • Weber CK, Liptay S, Wirth T, et al. Suppression of NF-κB activity by sulfasalazine is mediated by direct inhibition of IκB kinases α and β. Gastroenterology 2000;119(5):1209-18
  • Egan LJ, Mays DC, Huntoon CJ, et al. Inhibition of interleukin-1-stimulated NF-κB RelA/p65 phosphorylation by mesalamine is accompanied by decreased transcriptional activity. J Biol Chem 1999;274(37):26448-53
  • Sourbier C, Danilin S, Lindner V, et al. Targeting the nuclear factor-κB rescue pathway has promising future in human renal cell carcinoma therapy. Cancer Res 2007;67(24):11668-76
  • De Bosscher K, Vanden Berghe W, Haegeman G. The interplay between the glucocorticoid receptor and nuclear factor-κB or activator protein-1: molecular mechanisms for gene repression. Endocr Rev 2003;24(4):488-522
  • Auphan N, DiDonato JA, Rosette C, et al. Immunosuppression by glucocorticoids: inhibition of NF-κB activity through induction of IκB synthesis. Science 1995;270(5234):286-90
  • Bartlett JB, Dredge K, Dalgleish AG. The evolution of thalidomide and its IMiD derivatives as anticancer agents. Nat Rev Cancer 2004;4(4):314-22
  • Singhal S, Mehta J, Desikan R, et al. Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med 1999;341(21):1565-71
  • Chen J, Fang Y. A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochem Pharmacol 2002;64(7):1071-7
  • Romano MF, Avellino R, Petrella A, et al. Rapamycin inhibits doxorubicin-induced NF-κB/Rel nuclear activity and enhances the apoptosis of melanoma cells. Eur J Cancer 2004;40(18):2829-36
  • Lin YG, Kunnumakkara AB, Nair A, et al. Curcumin inhibits tumor growth and angiogenesis in ovarian carcinoma by targeting the nuclear factor-κB pathway. Clin Cancer Res 2007;13(11):3423-30
  • Lee KW, Kim JH, Lee HJ, Surh YJ. Curcumin inhibits phorbol ester-induced up-regulation of cyclooxygenase-2 and matrix metalloproteinase-9 by blocking ERK1/2 phosphorylation and NF-κB transcriptional activity in MCF10A human breast epithelial cells. Antioxid Redox Signal 2005;7(11-12):1612-20
  • Aggarwal S, Takada Y, Singh S, et al. Inhibition of growth and survival of human head and neck squamous cell carcinoma cells by curcumin via modulation of nuclear factor-κB signaling. Int J Cancer 2004;111(5):679-92
  • Shishodia S, Potdar P, Gairola CG, Aggarwal BB. Curcumin (diferuloylmethane) down-regulates cigarette smoke-induced NF-κB activation through inhibition of IκBα kinase in human lung epithelial cells: correlation with suppression of COX-2, MMP-9 and cyclin D1. Carcinogenesis 2003;24(7):1269-79
  • Kumar AP, Garcia GE, Ghosh R, et al. 4-Hydroxy-3-methoxybenzoic acid methyl ester: a curcumin derivative targets Akt/NFκB cell survival signaling pathway: potential for prostate cancer management. Neoplasia 2003;5(3):255-66
  • Alok Bharti C, Aggarwal BB. Nuclear factor-κB and cancer: its role in prevention and therapy. Biochem Pharmacol 2002;64:883-8
  • Jang M, Cai L, Udeani GO, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997;275(5297):218-20
  • Bhardwaj A, Sethi G, Vadhan-Raj S, et al. Resveratrol inhibits proliferation, induces apoptosis, and overcomes chemoresistance through down-regulation of STAT3 and nuclear factor-κB-regulated antiapoptotic and cell survival gene products in human multiple myeloma cells. Blood 2007;109(6):2293-302
  • Yang CS, Maliakal P, Meng X. Inhibition of carcinogenesis by tea. Ann Rev Pharmacol Toxicol 2002;42:25-54
  • Ahmad N, Gupta S, Mukhtar H. Green tea polyphenol epigallocatechin-3-gallate differentially modulates nuclear factor κB in cancer cells versus normal cells. Arch Biochem Biophys 2000;376(2):338-46
  • Yip-Schneider MT, Nakshatri H, Sweeney CJ, et al. Parthenolide and sulindac cooperate to mediate growth suppression and inhibit the nuclear factor-κB pathway in pancreatic carcinoma cells. Mol Cancer Ther 2005;4(4):587-94
  • Hewamana S, Alghazal S, Lin TT, et al. The NF-κB subunit, Rel A, is associated with in vitro survival and clinical disease progression in chronic lymphocytic leukaemia and represents a promising therapeutic target. Blood 2008
  • Lee JH, Koo TH, Hwang BY, Lee JJ. Kaurane diterpene, kamebakaurin, inhibits NF-κB by directly targeting the DNA-binding activity of p50 and blocks the expression of antiapoptotic NF-κB target genes. J Biol Chem 2002;277(21):18411-20
  • Dhanalakshmi S, Singh RP, Agarwal C, Agarwal R. Silibinin inhibits constitutive and TNFα-induced activation of NF-κB and sensitizes human prostate carcinoma DU145 cells to TNFα-induced apoptosis. Oncogene 2002;21(11):1759-67
  • Tyagi A, Raina K, Singh RP, et al. Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice. Mol Cancer Ther 2007;6(12 Pt 1):3248-55

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.